Peripheral Artery Disease (PAD)

Peripheral artery disease (PAD) has been recognized as a clinical entity for centuries, though early physicians lacked the tools to understand its underlying mechanism. Ancient Egyptian papyri describe cases of gangrenous extremities, and surgeons during the Napoleonic wars documented limb ischemia in soldiers whose arteries were obstructed by trauma or disease. However, it was not until the rise of modern pathology and vascular surgery in the nineteenth and twentieth centuries that clinicians began to connect the progressive narrowing of peripheral arteries to atherosclerosis — the same disease process responsible for coronary artery disease and stroke. Today, PAD affects more than 200 million people worldwide and serves as both a major cause of limb morbidity and a powerful predictor of systemic cardiovascular events.

Despite these advances, PAD remains underdiagnosed and undertreated relative to coronary artery disease. The central questions driving contemporary study of PAD are: What molecular and hemodynamic processes drive atherosclerotic plaque development in the peripheral vasculature? How does diminished perfusion produce tissue ischemia, claudication, and ultimately critical limb-threatening ischemia? And how can we leverage our understanding of its pathophysiology to improve early detection, risk stratification, and evidence-based management?

PAD is defined as the atherosclerotic occlusive disease of arteries supplying the lower extremities, though it can also affect the upper extremities, mesenteric, and renal vasculature. Understanding its pathophysiology requires familiarity with several interconnected concepts — from the biology of the arterial wall to the hemodynamics of stenotic flow.

The progression depicted above highlights a critical hemodynamic principle: blood flow through a stenotic vessel does not decrease linearly with diameter. According to Poiseuille's law, flow is proportional to the fourth power of the radius, meaning that a 50% reduction in luminal diameter produces an approximately 94% reduction in flow (if other variables remain constant). This explains why patients can remain asymptomatic until the stenosis exceeds roughly 50–70% — a phenomenon called hemodynamic compensation. Collateral vessels dilate and proliferate to partially restore downstream perfusion, but once the stenosis becomes critical, collateral reserve is exhausted and ischemic symptoms emerge.

The pathophysiology of PAD involves a cascade of molecular, cellular, and hemodynamic events. Although atherosclerosis is the dominant etiology (accounting for >95% of cases), understanding the quantitative relationships between vessel geometry and blood flow is essential for interpreting diagnostic findings and anticipating clinical outcomes.

Hemodynamic Principles in Stenotic Arteries

Molecular Pathogenesis: From Endothelial Injury to Plaque Formation

The pathogenesis of atherosclerosis in PAD mirrors that in coronary disease but shows a predilection for arterial bifurcations and areas of disturbed laminar flow in the lower extremities. The process begins with endothelial injury, triggered by risk factors such as hypertension, dyslipidemia, cigarette smoking, diabetes mellitus, and hyperhomocysteinemia. Damaged endothelial cells upregulate adhesion molecules (VCAM-1, ICAM-1, selectins), which recruit circulating monocytes into the subendothelial space. These monocytes differentiate into macrophages and engulf oxidized low-density lipoprotein (oxLDL), transforming into foam cells — the hallmark of the early fatty streak.

As the lesion matures, vascular smooth muscle cells migrate from the media into the intima and proliferate, secreting extracellular matrix components (collagen, elastin, proteoglycans) that form a fibrous cap overlying the lipid-rich necrotic core. Continued inflammation weakens the cap through the action of matrix metalloproteinases (MMPs) secreted by activated macrophages. If the cap ruptures, the thrombogenic core is exposed to circulating blood, precipitating acute thrombus formation — the mechanism behind acute limb ischemia. In PAD, however, the more common clinical course is gradual plaque growth with progressive luminal narrowing rather than acute plaque rupture.

Ischemia–Reperfusion Injury and Skeletal Muscle Effects

Chronic ischemia in PAD produces structural and metabolic changes within skeletal muscle. Mitochondrial dysfunction develops as a consequence of recurrent hypoxia, leading to impaired oxidative phosphorylation and increased reliance on anaerobic glycolysis. This metabolic shift causes lactate accumulation, local acidosis, and the exercise-induced pain characteristic of claudication. Over time, repeated ischemia–reperfusion cycles generate reactive oxygen species (ROS), which further damage endothelium and skeletal muscle fibers. Type II (fast-twitch) muscle fibers are selectively lost, and fibrosis replaces functional myocytes. These changes explain why patients with PAD experience exercise intolerance that may persist even after successful revascularization.

Several classification systems have been developed to stage the clinical severity of PAD. The two most widely used are the Fontaine classification (European) and the Rutherford classification (North American). Both systems correlate clinical symptoms with disease severity, but the Rutherford system adds objective hemodynamic criteria, making it more useful for clinical trials and surgical decision-making.

A 68-year-old male with a 40-pack-year smoking history and type 2 diabetes presents with bilateral calf cramping after walking two blocks. On physical examination, the right dorsalis pedis pulse is diminished and the right posterior tibial pulse is absent. You obtain Doppler blood pressure measurements: right ankle systolic pressures are 80 mmHg (dorsalis pedis) and 72 mmHg (posterior tibial); left ankle systolic pressures are 110 mmHg (dorsalis pedis) and 105 mmHg (posterior tibial). Brachial systolic pressures are 150 mmHg (right arm) and 145 mmHg (left arm). Calculate the ABI for each leg and interpret the results.

The diagnosis and management of PAD span a continuum from non-invasive screening to endovascular and surgical revascularization. Selecting the appropriate diagnostic test depends on the clinical question, while management is guided by disease severity and functional impairment.

A critical concept for healthcare students to internalize is that PAD is not merely a disease of the legs. It is a systemic marker of atherosclerotic burden. Patients diagnosed with PAD have a 3- to 6-fold increased risk of death from cardiovascular causes compared to age-matched controls without PAD. Approximately 60% of patients with PAD have significant concomitant coronary artery disease, and 30% have cerebrovascular disease. The five-year mortality rate for patients with CLTI approaches 50%, rivaling that of many malignancies.

Looking beyond the current paradigm, emerging research is exploring the role of inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-6), novel imaging techniques (contrast-enhanced ultrasound perfusion imaging, photoacoustic imaging), and gene therapy-based angiogenesis strategies for patients with no-option CLTI. The COMPASS trial demonstrated that low-dose rivarelbaan combined with aspirin significantly reduces major adverse limb events in patients with PAD, suggesting that the prothrombotic state in PAD may benefit from dual-pathway inhibition beyond traditional antiplatelet therapy alone.